HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Rubén Queiro Selected Research

Biological Therapy

9/2018Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis.
7/2015The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients.
9/2011[Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Rubén Queiro Research Topics

Disease

16Psoriatic Arthritis
01/2021 - 03/2003
15Psoriasis (Pustulosis Palmaris et Plantaris)
10/2019 - 03/2003
5Arthritis (Polyarthritis)
01/2022 - 03/2003
4Pain (Aches)
01/2022 - 02/2002
4Ankylosing Spondylitis
06/2020 - 10/2011
2Inflammation (Inflammations)
11/2021 - 06/2021
2Hypertension (High Blood Pressure)
03/2016 - 09/2014
1Spondylitis
01/2022
1Infections
11/2021
1Axial Spondyloarthritis
01/2021
1Metabolic Syndrome (Dysmetabolic Syndrome X)
06/2020
1Fatigue
06/2020
1Obesity
06/2020
1Dyslipidemias (Dyslipidemia)
09/2014
1Cardiovascular Diseases (Cardiovascular Disease)
09/2014
1Type 2 Diabetes Mellitus (MODY)
09/2014
1Joint Diseases (Joint Disease)
07/2014
1Spondylarthritis (Spinal Arthritis)
10/2011
1Rheumatic Diseases (Rheumatism)
09/2011
1Bursitis (Adhesive Capsulitis)
10/2010
1Spondylarthropathies
10/2010
1Disease Susceptibility (Diathesis)
03/2003
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
07/2002
1Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome)
07/2002
1Pre-Eclampsia (Preeclampsia)
07/2002
1Back Pain (Backache)
02/2002
1Uveitis
02/2002

Drug/Important Bio-Agent (IBA)

6Biological ProductsIBA
10/2019 - 07/2015
4ametantrone (HAQ)IBA
01/2022 - 11/2020
4HLA-C Antigens (HLA-C)IBA
10/2016 - 07/2012
3Pharmaceutical PreparationsIBA
01/2021 - 07/2015
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2019 - 06/2015
3HLA-C*06 antigenIBA
06/2015 - 07/2014
2Ustekinumab (CNTO 1275)FDA Link
10/2018 - 01/2018
2Antirheumatic Agents (DMARD)IBA
09/2018 - 01/2017
2HLA-B Antigens (HLA-B)IBA
10/2016 - 07/2014
2DNA (Deoxyribonucleic Acid)IBA
07/2015 - 09/2014
2HLA-B27 Antigen (HLA B27 Antigen)IBA
03/2003 - 02/2002
1Transcription Factors (Transcription Factor)IBA
11/2021
1Biomarkers (Surrogate Marker)IBA
06/2021
1secukinumabIBA
01/2021
1Prostaglandins AIBA
06/2020
1NexusIBA
01/2020
1apremilastIBA
01/2020
1Adalimumab (Humira)FDA Link
10/2019
1Immunoglobulins (Immunoglobulin)IBA
10/2018
1Monoclonal AntibodiesIBA
10/2018
1Methotrexate (Mexate)FDA LinkGeneric
07/2018
1Proteins (Proteins, Gene)FDA Link
05/2017
1LipidsIBA
03/2016
1Interleukin-12 (IL 12)IBA
07/2015
1AntibodiesIBA
06/2015
1AntigensIBA
05/2012
1Etanercept (Enbrel)FDA Link
10/2011
1HLA Antigens (Human Leukocyte Antigens)IBA
03/2003
1Complement System Proteins (Complement)IBA
07/2002
1Antiphospholipid AntibodiesIBA
07/2002
1HLA-DR13 antigenIBA
02/2002

Therapy/Procedure

5Therapeutics
01/2021 - 10/2010
3Biological Therapy
09/2018 - 09/2011